NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $0.58 +0.01 (+1.76%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends About Bolt Biotherapeutics Stock (NASDAQ:BOLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.56▼$0.5850-Day Range$0.56▼$0.6852-Week Range$0.54▼$1.56Volume158,235 shsAverage Volume165,103 shsMarket Capitalization$22.14 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company OverviewBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More… The #1 ETF for monthly income (Ad)We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.Click here to get the full story >> Bolt Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks71st Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 339th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bolt Biotherapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently decreased by 44.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.26% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently decreased by 44.77%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment-0.49 News SentimentBolt Biotherapeutics has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for BOLT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock News HeadlinesWhat is HC Wainwright's Estimate for BOLT FY2024 Earnings?November 16, 2024 | americanbankingnews.comBolt Biotherapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 15, 2024 | finance.yahoo.comThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.November 22, 2024 | Investors Alley (Ad)Bolt Biotherapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer LookNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue EstimatesNovember 13, 2024 | msn.comBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | markets.businessinsider.comBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $1.12 at the beginning of 2024. Since then, BOLT shares have decreased by 48.3% and is now trading at $0.5786. View the best growth stocks for 2024 here. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its earnings results on Tuesday, November, 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04. The business earned $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative trailing twelve-month return on equity of 69.46%. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Bolt Biotherapeutics' major shareholders? Top institutional investors of Bolt Biotherapeutics include Geode Capital Management LLC (0.92%) and FMR LLC (0.30%). Insiders that own company stock include Holdings A/S Novo, Edgar Engleman, Vivo Capital Viii, Llc and William P Quinn. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV). Company Calendar Last Earnings11/12/2024Today11/22/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$8.00 Low Stock Price Target$1.00 Potential Upside/Downside+525.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,200,000.00 Net Margins-665.56% Pretax Margin-665.56% Return on Equity-69.46% Return on Assets-48.55% Debt Debt-to-Equity Ratio0.21 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$9.78 million Price / Sales2.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.30Miscellaneous Outstanding Shares38,273,000Free Float26,447,000Market Cap$21.43 million OptionableNot Optionable Beta0.92 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BOLT) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump Returns...Inflation Fears SkyrocketTrump's back in the White House, but here's what they're not telling you: his plans could cause inflation to s...Oasis Gold | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.